The Peptide Authority
Peer-reviewed · Updated weekly

Search Peer-Reviewed Peptide Research

Search a continuously expanding index of published peptide research, with direct links to PubMed records, DOI pages, study protocols, and original journal sources. Every study is drawn exclusively from peer-reviewed journals indexed in MEDLINE and Cochrane, the same sources relied on by clinicians and researchers worldwide.

Advertisement728 × 90: Leaderboard

Compound Index

Featured Peptide Compounds

Each compound includes molecular formula, mechanism of action, clinical status, and linked primary literature.

Latest Evidence

Recently Indexed Studies

Clinical trials, RCTs, and preclinical findings from journals indexed in this library.

Clinical TrialSemaglutide

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

The New England journal of medicine|2025
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York.
Aronne, LJ., Horn, DB., le Roux, CW., Ho, W., Falcon, BL., Gomez Valderas, E.

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confi

Key Finding

A total of 751 participants underwent randomization.

DOI: 10.1056/NEJMoa2416394Read full
RCTSemaglutide

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

The New England journal of medicine|2023
From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Clev
Lincoff, AM., Brown-Frandsen, K., Colhoun, HM., Deanfield, J., Emerson, SS., Esbjerg, S.

Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event ana

Key Finding

A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.

DOI: 10.1056/NEJMoa2307563Read full
RCTSemaglutide

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Lancet (London, England)|2021
Diabetes Research Centre, University of Leicester, Leicester, UK
Davies, M., Færch, L., Jeppesen, OK., Pakseresht, A., Pedersen, SD., Perreault, L.

This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes. This double-blind, double-dummy, phase 3, superiority study enrolled adults with a body-mass index of at least 27 kg/m2 and glycated haemoglobin 7-10% (53-86 mmol/mol) who had been diagnosed with type 2 diabetes at least 180 days before screening. Patients were recruited from 149 outpatient clinics in 12 countries across Europe, North America, South America, the Middle East, South Africa, and Asia. Patients were randomly allocated (1:1:1) via an interactive web-response system and stratified by background glucose-lowering medication and glycated haemoglobin, to subcutaneous injection of semaglutide 2·4 mg,

Key Finding

From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2·4 mg (n=404), semaglutide 1·0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis.

DOI: 10.1016/S0140-6736(21)00213-0Read full
Advertisement728 × 90: Leaderboard

Also Indexed

More From the Index

Research Areas

Browse by Therapeutic Area

Organized by clinical domain. Each area links directly to the indexed literature.

Explore Retatrutide research
Advertisement728 × 90: Leaderboard

Research drawn from

The LancetNEJM EvidenceJournal of Clinical InvestigationFrontiers in PharmacologyBiomolecules (MDPI)Peptides (Elsevier)

Evidence Briefing

The Peptide Evidence Brief

Twice each month, receive the most important newly indexed studies, clinical trial updates, evidence summaries, and research developments, selected exclusively from trusted peer-reviewed journals.

Concise summaries with direct links to original publications. Quality over quantity. No promotional content.

Peer-reviewed sources onlyPublished twice monthlyNo promotional content

No spam. Unsubscribe at any time. We never share your data.